Modern Retina | Ophthalmology News, Events & Expert Insights
Ali Erginay, MD, MD, spoke about the important developments in retinal imaging, specifically the Red-Blue-Green (RGB) imaging modalities during his interview with Ophthalmology Times Europe, which took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.
Dealing with complications of silicone oil - Modern Retina
Sep 2, 2022 · Re-detachment after silicone oil removal is a major complication, with rates varying up to 30%. Suspected ERP and ERMs can be diagnosed by direct examination and OCT and removed when silicone oil is removed from the eye. Peripheral 360-degree laser retinopexy and scleral encircling band significantly diminish the rate of re-detachment.
Ocular Therapeutix Inc. screens and doses the first 3 subjects in …
Feb 13, 2024 · These 3 participants have received their first aflibercept injection for the treatment of wet AMD. Ocular Therapeutix Inc. screened the first 3 subjects in the Phase 3 SOL-1 clinical trial of AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD).
EURETINA
EURETINA 2024: An overview of the SING-IMT implant with Alfonso Savastano, MD, PhD. Hattie Hayes; Martin David Harp. September 30th 2024. Alfonso Savastano, MD, PhD spoke about the SING-IMT implant during his interview with Ophthalmology Times Europe, which took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.
Ocugen doses first patient in Phase 3 liMeliGhT clinical trial for …
Jun 21, 2024 · OCU400 is a gene-agnostic modifier gene therapy product based on nuclear hormone receptor (NHR) gene, NR2E3. Ocugen Inc announced the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). “Each clinical milestone achieved by ...
Achromatopsia: Understanding the rare inherited retinal disease
Aug 27, 2018 · Achromatopsia is an autosomal recessive disease that affects approximately 1:30,000 individuals and is associated with complete loss of cone function. It is most commonly caused by mutations in the CNGB3 and CNGA3 genes and is associated with severely reduced visual acuity and extreme photosensitivity, resulting in daytime blindness.
Isopropyl nitrate poppers pose maculopathy risk - Modern Retina
Nov 23, 2017 · Poppers consist of volatile aromatic nitrates, typically in colourless liquids. They cause vasodilation and were originally developed for the treatment of angina. Side effects include reduced blood pressure; headache; flushing; tachycardia; dizziness; and involuntary muscle relaxation, including of vaginal muscles and the sphincter.
WIO 2024: A conversation with WIO President, Christina Y. Weng, …
Aug 22, 2024 · Christina Y. Weng, MD, MBA discussed what attendees, both virtually and in-person, can expect from this year's Women in Ophthalmology Summer Symposium meeting in Carlsbad, California. The meeting will take place August 22-25, 2024. Video Transcript: Editor's note: The below transcript has been lightly edited for clarity.
EURETINA 2023: Ali Erginay, MD, discusses advancements in ultra ...
Oct 6, 2023 · Loaded 0%. This week, the 23rd annual EURETINA Congress is underway in Amsterdam, the Netherlands. Ali Erginay, MD, spoke with our team about his presentation, titled "Introducing optomap® Ultra-widefield Colour Red-Green-Blue Multimodal Imaging." Here's what he had to say about the latest technology in ultra-widefield imaging.
ALG-1001: Turning off the machinery of angiogenesis - Modern …
Oct 11, 2017 · ALG-1001 (Luminate, Allegro Ophthalmics), a first-in-class integrin peptide therapy, met the primary endpoint of vision non-inferiority to bevacizumab (Avastin, Genentech Inc.), an anti-vascular endothelial growth factor therapy (anti-VEGF), with 12-week durability in a population of patients with mostly chronic diabetic macular edema (DME).